Century Therapeutics Reports Sharply Reduced Net Loss, Strong Revenue Growth, and Extended Cash Runway

summarizeSummary

Century Therapeutics announced a significant reduction in its 2025 net loss and a substantial increase in collaboration revenue, alongside an extended cash runway into Q1 2029, driven by a recent $135 million private placement.

check_boxKey Events

• Significant Net Loss Reduction

  Net loss decreased to $9.6 million for the year ended December 31, 2025, compared to a net loss of $126.6 million for the same period in 2024.

• Substantial Collaboration Revenue Growth

  Collaboration revenue surged to $109.2 million for the year ended December 31, 2025, up from $6.6 million in 2024.

• Extended Cash Runway

  A $135 million private placement completed in January 2026 extended the company's cash, cash equivalents, and investments to support operations into the first quarter of 2029.

• Key Pipeline Advancement

  IND submission for the lead Type 1 Diabetes program (CNTY-813) is expected in Q4 2026, with initial clinical data anticipated in 2H 2027.

auto_awesomeAnalysis

This 8-K filing, accompanying the full 10-K, details a strong financial turnaround for Century Therapeutics in 2025. The company dramatically reduced its net loss and saw a massive increase in collaboration revenue, primarily from a terminated Bristol-Myers Squibb agreement. Critically, a $135 million private placement completed in January 2026 has extended the company's cash runway into the first quarter of 2029, significantly de-risking its operations and providing capital to advance its pipeline. Positive updates on key programs, including IND submission timelines for CNTY-813 (Type 1 Diabetes) and CNTY-308 (CAR-iT cell therapy), further bolster investor confidence in the company's strategic execution and long-term prospects.